WO1998048045A2 - Verfahren zur nichtinvasiven erkennung bösartiger tumoren der lunge - Google Patents
Verfahren zur nichtinvasiven erkennung bösartiger tumoren der lunge Download PDFInfo
- Publication number
- WO1998048045A2 WO1998048045A2 PCT/DE1998/001082 DE9801082W WO9848045A2 WO 1998048045 A2 WO1998048045 A2 WO 1998048045A2 DE 9801082 W DE9801082 W DE 9801082W WO 9848045 A2 WO9848045 A2 WO 9848045A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- detection
- sections
- hybridization
- tumor marker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the invention relates to a method for the detection of malignant lung tumors in humans and the use of breathing air for the isolation of genomic DNA and for the early detection of malignant lung tumors.
- Lung tumors are among the most common cancers worldwide and rank first in mortality statistics. The problem of these diseases is particularly evident in the fact that an early diagnosis has so far not been possible and that the prognosis is generally fatal after the classic diagnosis has been made.
- Lung tumors are currently being diagnosed using imaging methods (X-ray examinations), in special cases using computed tomography. In this way, it is usually only possible to diagnose manifest tumors that are space-consuming processes.
- a histological examination is carried out after any abnormalities in the imaging examination. The acquisition of sample material is tied to surgical manipulation. It is therefore not without problems and, as a rule, must also be repeated.
- a number of such molecular tumor markers in lung tumors are known to be genetically modified.
- Molecular tumor markers in question include the proto-oncogene Kira and the tumor suppressor genes.
- the frequency of mutations in these tumor markers is between 50-70%.
- the invention is based on the knowledge that the changes in the DNA sequences of these genes often occur at an early stage of tumor development. Finding and characterizing these changes clearly serves to make an early diagnosis.
- Such a detection method can only be used sensibly if a routine system for the examination of risk groups (smokers, miners, persons exposed to dust) is available.
- the invention was therefore based on the object of developing a detection method for the early detection of malignant lung tumors while avoiding complex x-ray examinations which are unsuitable for early diagnosis and surgical measures for obtaining test material.
- the molecular diagnosis of genetic aberrations of relevant tumor marker genes takes place directly from a breath condensate.
- the breathing condensate is obtained using commercially available breathing condensate collectors, with which the patient's exhaled air is transferred to a cooled collecting hose.
- the condensate obtained is then concentrated and is the starting material for isolating the patient's genomic DNA.
- the source of the DNA isolation are, on the one hand, exfoliated epitheal cells of the lungs contained in the respiratory condensate or so-called naked DNA contained in the condensate.
- DNA isolation is achieved using a highly sensitive extraction method according to claims 2-5.
- the lysate is thus incubated with a mineral carrier material for binding the DNA;
- the carrier material is preferably highly disperse, non-porous SiO 2 particles with a grain size of 7 nm-1 ⁇ m, preferably 40 nm, with a specific surface area of 10-300 m 2 / g, preferably 50 m 2 / g,
- the mineral carrier material with the bound genomic DNA is placed on a membrane made of polysulfone ether, which is located at the bottom of a microfilter vessel or a filter microtest plate, and is fixed on this membrane by centrifugation or by means of vacuum.
- a washing solution preferably made of ethanol, sodium chloride and Tris-HCl
- the nucleic acid is eluted from the carrier material with a low salt buffer, preferably from Tris-HCl and EDTA.
- the DNA obtained is now the starting material for selective enzymatic amplification reactions using classic molecular biological techniques. Depending on the objective, different tumor marker genes can be duplicated. The subsequent investigation of genetic changes is achieved using allele-specific hybridization reactions. This allows highly sensitive detection of mutated DNA sequence regions, even from mixed samples of healthy and mutated cells.
- the hybridization reaction is detected in the form of a direct enzymatic method in which the
- Hybridization probe is marked against
- the method is significantly simplified in that, instead of an indirect enzymatic detection method, a direct optical measurement of the probe marking is carried out. This allows the duration of such proof to be shortened considerably.
- the invention also relates to the use of breathing air, preferably in the form of condensates, for isolating DNA and for detecting malignant lung tumors in humans.
- the simple possibility of being able to use breathing air as a starting material for the detection method according to the invention represents a new development in medicine.
- the great advantage is that it is not only a simple and inexpensive method for routine examinations, in particular for the early detection of lung tumors Is available, but at the same time numerous sufferers are spared the pain of a painful examination.
- the breathing condensate is obtained using a commercially available exhaled air collector. About 150-300 l of air are collected and the breathing condensate is then concentrated.
- the DNA extraction is carried out by adding 500 ⁇ l lysis buffer binding buffer (guanidine isothiocyanate, N-lauryl-sarcosyl; DTT) and incubating for 5 min at room temperature. Add 10 ⁇ l of the DNA binding matrix (non-porous nanoparticles of pure silicon dioxide in aqueous solution) and incubate for 1 min. Transfer the total solution to a microcentrifugation column with a polysulfone ether membrane and centrifugation for 30 s at 10,000 xg and discarding the filtrate.
- lysis buffer binding buffer guanidine isothiocyanate, N-lauryl-sarcosyl; DTT
- the double-stranded amplification product is transferred via the biotin label to a streptavidin-coated microtest plate and the unbound strand is washed off by means of alkaline denaturation.
- Hybridization oligonucleotides are then used to hybridize against the DNa section of the Ki-ras gene immobilized on the plate surface. Very stringent washing steps remove all hybridization probes that are not clearly complementary to the target sequence and thus enable highly sensitive identification of single-base mutations.
- the hybridization oligonucleotides are provided with a label which is subsequently detected using standard methods.
- the characterization of the DNA sequence of the Ki-ras gene to be examined can be evaluated.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU76381/98A AU7638198A (en) | 1997-04-18 | 1998-04-14 | Method for non-invasive identification of malignant lung tumors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19717717A DE19717717B4 (de) | 1997-04-18 | 1997-04-18 | Verfahren zur nichtinvasiven Erkennung bösartiger Tumoren der Lunge |
DE19717717.4 | 1997-04-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998048045A2 true WO1998048045A2 (de) | 1998-10-29 |
WO1998048045A3 WO1998048045A3 (de) | 1999-01-28 |
Family
ID=7827862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1998/001082 WO1998048045A2 (de) | 1997-04-18 | 1998-04-14 | Verfahren zur nichtinvasiven erkennung bösartiger tumoren der lunge |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7638198A (de) |
DE (1) | DE19717717B4 (de) |
WO (1) | WO1998048045A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7364553B2 (en) | 2002-12-20 | 2008-04-29 | Amidex, Inc. | Breath aerosol management and collection system |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032616A2 (de) * | 1997-12-18 | 1999-07-01 | Invitek Gmbh | Verfahren zur isolierung von kurz- und langkettigen nukleinsäuren |
DE102006029926B4 (de) * | 2006-06-29 | 2008-11-20 | Siemens Ag | Anordnung und Verfahren zur Identifizierung von Personen |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001359A1 (de) * | 1993-07-01 | 1995-01-12 | Qiagen Gmbh | Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen |
WO1995013397A1 (en) * | 1993-11-12 | 1995-05-18 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection by analysis of sputum |
WO1995034569A1 (de) * | 1994-06-14 | 1995-12-21 | Invitek Gmbh | Universelles verfahren zur isolierung und reinigung von nukleinsäuren aus extrem geringen mengen sowie sehr stark verunreinigten unterschiedlichsten ausgangsmaterialien |
DE4422044A1 (de) * | 1994-06-14 | 1995-12-21 | Invitek Gmbh | Verfahren zur Isolierung, Reinigung und ggf. Lagerung von Nukleinsäuren |
DE19506887A1 (de) * | 1995-02-17 | 1996-08-22 | Invitek Gmbh | Verfahren zur simultanen Isolierung von genomischer DNS und hochreiner Total RNS |
WO1998008971A1 (de) * | 1996-08-26 | 1998-03-05 | Invitek Gmbh | Verfahren zum nachweis klinisch relevanter veränderungen der dns-sequenz des ki-ras-onkogens, seine verwendung und testkit zur früherkennung von tumoren |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4772559A (en) * | 1985-10-10 | 1988-09-20 | Monell Chemical Senses Center | Method of detecting the presence of bronchogenic carcinoma by analysis of expired lung air |
DE3932784C3 (de) * | 1989-09-30 | 2002-08-01 | Nmi Univ Tuebingen | Verfahren zur Gewinnung nichtflüchtiger Substanzen als analytisches Probenmaterial aus der menschlichen Atemluft |
US5465728A (en) * | 1994-01-11 | 1995-11-14 | Phillips; Michael | Breath collection |
EP0759169B1 (de) * | 1994-05-13 | 1998-01-14 | Filt Forschungsgesellschaft Für Lungen- Und Thoraxerkrankungen Mbh | Verfahren und vorrichtung zum sammeln von ausgeatmetem atemkondensat |
-
1997
- 1997-04-18 DE DE19717717A patent/DE19717717B4/de not_active Expired - Fee Related
-
1998
- 1998-04-14 AU AU76381/98A patent/AU7638198A/en not_active Abandoned
- 1998-04-14 WO PCT/DE1998/001082 patent/WO1998048045A2/de active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001359A1 (de) * | 1993-07-01 | 1995-01-12 | Qiagen Gmbh | Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen |
WO1995013397A1 (en) * | 1993-11-12 | 1995-05-18 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection by analysis of sputum |
WO1995034569A1 (de) * | 1994-06-14 | 1995-12-21 | Invitek Gmbh | Universelles verfahren zur isolierung und reinigung von nukleinsäuren aus extrem geringen mengen sowie sehr stark verunreinigten unterschiedlichsten ausgangsmaterialien |
DE4422044A1 (de) * | 1994-06-14 | 1995-12-21 | Invitek Gmbh | Verfahren zur Isolierung, Reinigung und ggf. Lagerung von Nukleinsäuren |
DE19506887A1 (de) * | 1995-02-17 | 1996-08-22 | Invitek Gmbh | Verfahren zur simultanen Isolierung von genomischer DNS und hochreiner Total RNS |
WO1998008971A1 (de) * | 1996-08-26 | 1998-03-05 | Invitek Gmbh | Verfahren zum nachweis klinisch relevanter veränderungen der dns-sequenz des ki-ras-onkogens, seine verwendung und testkit zur früherkennung von tumoren |
Non-Patent Citations (2)
Title |
---|
BERNDT ET AL.: "A MICROPLATE ASSAY FOR K-ras GENOTYPING" EUR.J.CLIN.CHEM.CLIN.BIOCHEM., Bd. 34, 1996, Seiten 837-840, XP002082636 * |
HESKETH: "THE ONCOGENE FACTS BOOK" 1995 , ACADEMIC PRESS , LONDON,GB XP002082641 214530 RAS siehe Seite 225 - Seite 234 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7364553B2 (en) | 2002-12-20 | 2008-04-29 | Amidex, Inc. | Breath aerosol management and collection system |
Also Published As
Publication number | Publication date |
---|---|
DE19717717A1 (de) | 1998-10-22 |
DE19717717B4 (de) | 2007-08-02 |
WO1998048045A3 (de) | 1999-01-28 |
AU7638198A (en) | 1998-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69828392T2 (de) | Verfahren zur Herstellung eines diagnostischen Standard-Gentranskriptionsmusters | |
US10351900B2 (en) | Method for identifying pathogens of bacterial infectious diseases by using bacteria-derived nanovesicles | |
Riviere et al. | Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease | |
EP1100873B1 (de) | Krebszellen aus zellhaltigen körperflüssigkeiten, deren isolierung, verwendung sowie diese enthaltende mittel | |
DE60030281T2 (de) | Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen | |
DE69919005T2 (de) | Methode zur erhaltung von menschlichen dna hautproben mittels einer adhesiven folie | |
DE60026624T2 (de) | Verfahren und Zusammensetzungen für die Detektion pathologischer Ereignisse | |
EP0920535B1 (de) | Verfahren zum nachweis klinisch relevanter veränderungen der dns-sequenz des ki-ras-onkogens, seine verwendung und testkit zur früherkennung von tumoren | |
Ho et al. | A novel point mutation in the McLeod syndrome gene in neuroacanthocytosis | |
DE60104149T2 (de) | Vorrichtung zur analyse und/oder zur behandlung mit einem flexiblen schaft | |
DE60219589T2 (de) | Spezifisch vom Genom von Mycobacterium tuberculosis deletierte Sequenzen und deren Verwendung in der Diagnostik und als Vakzine | |
DE60035977T2 (de) | MIT FTA BESCHICHTETER TRäGER ZUR VERWENDUNG ALS MOLEKULARES DIAGNOSEMITTEL | |
US8889597B2 (en) | Sequences associated with TDP-43 proteinopathies and methods of using the same | |
WO1998048045A2 (de) | Verfahren zur nichtinvasiven erkennung bösartiger tumoren der lunge | |
Morley et al. | Is aplastic anaemia due to abnormality of DNA? | |
DE10234524A1 (de) | Nukleinsäurearray | |
DE60216570T2 (de) | Verfahren zum nachweis von alzheimer-krankheit | |
EP1448792A1 (de) | Diagnose-kit, dns-chip sowie verfahren zur diagnostik oder behandlungskontrolle bei hodenkrebs | |
CN109536619A (zh) | 一种试剂盒、方法、引物对和探针及其应用 | |
CN108531569A (zh) | 用于强迫症与精神分裂症、抑郁症甄别的基因标志物及其应用 | |
DE102020209412B4 (de) | Mittel und Verfahren zur An- oder Abreicherung und zum Nachweis von Coronaviren | |
EP0991780A2 (de) | Verfahren und testkit zum nachweis bösartiger tumore | |
DE102017126248B4 (de) | ERGIC1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesonderemonozytischem myeloid-abgeleiteten Suppressor-Zellen (mMDSCs) | |
EP3875957A1 (de) | Verfahren und vorrichtung zur diagnose eines verdachts einer virusinfektion | |
DE102017125019B4 (de) | PDCD1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere PD1+ Zellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998544721 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |